Evelo Biosciences (NASDAQ:EVLO) and Antibe Therapeutics (OTCMKTS:ATBPD) Financial Survey

Profitability

This table compares Evelo Biosciences and Antibe Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
Antibe Therapeutics	-273.96%	-150.49%	-98.51%

Valuation & Earnings

This table compares Evelo Biosciences and Antibe Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53 million	($13.01)	0.00
Antibe Therapeutics	$7.51 million	0.00	-$14.54 million	($0.60)	N/A

Antibe Therapeutics has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

0.3% of Evelo Biosciences shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Evelo Biosciences has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Antibe Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Summary

Evelo Biosciences beats Antibe Therapeutics on 7 of the 10 factors compared between the two stocks.

About Evelo Biosciences

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

About Antibe Therapeutics

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.